{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+Injection&page=5", "query": { "intervention": "Sham Injection", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 372, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+Injection&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sham+Injection&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T18:05:41.954Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05151731", "title": "A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Vamikibart", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 394, "start_date": "2021-12-31", "completion_date": "2025-04-21", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 36, "location_summary": "Arcadia, California • Poway, California • Sacramento, California + 33 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05151731" }, { "nct_id": "NCT02222207", "title": "Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Regorafenib, ophthalmic oily suspension (BAY73-4506)", "type": "DRUG" }, { "name": "Sham IVT", "type": "PROCEDURE" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 52, "start_date": "2014-10", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 37, "location_summary": "Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222207" }, { "nct_id": "NCT00168298", "title": "A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Retinal Vein Occlusion" ], "interventions": [ { "name": "700 µg Dexamethasone", "type": "DRUG" }, { "name": "350 µg Dexamethasone", "type": "DRUG" }, { "name": "Sham Injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2004-11-01", "completion_date": "2008-09-05", "has_results": true, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00168298" }, { "nct_id": "NCT00320775", "title": "Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "VEGF Trap", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 51, "start_date": "2005-06", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2015-03-18", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 8, "location_summary": "Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320775" }, { "nct_id": "NCT01414153", "title": "Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age-related Macular Degeneration" ], "interventions": [ { "name": "4.0 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea", "type": "DRUG" }, { "name": "sham injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 158, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 44, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414153" }, { "nct_id": "NCT02050828", "title": "The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema (DME)" ], "interventions": [ { "name": "AKB-9778", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerpio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 144, "start_date": "2014-01", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2017-03-16", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 39, "location_summary": "Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more", "locations": [ { "city": "Pheonix", "state": "Arizona" }, { "city": "Pheonix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02050828" }, { "nct_id": "NCT04003012", "title": "Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Leukemia-Lymphoma" ], "interventions": [ { "name": "EMLA", "type": "DRUG" }, { "name": "Lidocaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CAMC Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 10, "start_date": "2019-07-19", "completion_date": "2021-07-20", "has_results": true, "last_update_posted_date": "2023-03-09", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 1, "location_summary": "Charleston, West Virginia", "locations": [ { "city": "Charleston", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003012" }, { "nct_id": "NCT06430385", "title": "ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome" ], "interventions": [ { "name": "ION440", "type": "DRUG" }, { "name": "Sham procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "2 Years to 65 Years · Male only" }, "enrollment_count": 48, "start_date": "2024-10-21", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 8, "location_summary": "San Diego, California • Aurora, Colorado • Baltimore, Maryland + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06430385" }, { "nct_id": "NCT03622580", "title": "A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "Faricimab", "type": "DRUG" }, { "name": "Sham Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2018-09-05", "completion_date": "2021-09-03", "has_results": true, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 85, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03622580" }, { "nct_id": "NCT03953079", "title": "A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "Drug: GB-102", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Graybug Vision", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 56, "start_date": "2019-09-26", "completion_date": "2021-06-03", "has_results": true, "last_update_posted_date": "2022-01-19", "last_synced_at": "2026-10-18T18:05:41.954Z", "location_count": 33, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03953079" } ] }